A panelist discusses a typical lower-risk myelodysplastic syndrome case managed with luspatercept over ...

A panelist discusses the evolving role of luspatercept in low-risk myelodysplastic syndrome, highlighting its broad efficacy beyond SF3B1 mutations, its advantage in reducing transfusions and ...

Panelists discuss how clinical trial data support the consistent efficacy of oral selective estrogen receptor degraders (SERDs) across diverse metastatic breast cancer subgroups—including patients ...

Panelists discuss the evolving management of estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, highlighting the clinical impact of oral selective estrogen receptor degraders ...

An expert highlights that the future of metastatic castration-resistant prostate cancer (mCRPC) treatment is advancing with novel drug classes such as radioligand therapies, proteolysis-targeting ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Recent oncology breakthroughs showcase innovative treatments and approvals, enhancing patient outcomes in CLL, RCC, NSCLC, ...

Theresa Medina, MD, associate professor of medicine-medical oncology at the University of Colorado Cancer Center, Anschutz ...

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert ...

Recent studies reveal promising outcomes for discontinuing TKI therapy in select patients with Philadelphia ...

FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...